Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer DOI Creative Commons
Desh Deepak Singh, Shafiul Haque, Youngsun Kim

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 10, 2024

Triple-negative breast cancer (TNBC) stands as the most complex and daunting subtype of affecting women globally. Regrettably, treatment options for TNBC remain limited due to its clinical complexity. However, immunotherapy has emerged a promising avenue, showing success in developing effective therapies advanced cases improving patient outcomes. Improving treatments involves reducing side effects, minimizing systemic toxicity, enhancing efficacy. Unlike traditional immunotherapy, engineered nonmaterial's can precisely target TNBC, facilitating immune cell access, antigen presentation, triggering lasting responses. Nanocarriers with enhanced sensitivity specificity, specific cellular absorption, low toxicity are gaining attention. Nanotechnology-driven immunoengineering strategies focus on targeted delivery systems using multifunctional molecules precise tracking, diagnosis, therapy TNBC. This study delves into TNBC's tumour microenvironment (TME) remodeling, therapeutic resistance, nanotechnology.

Язык: Английский

Functional epitope mapping of cell surface glucose-regulated protein 94: A combinatorial approach for therapeutic targeting DOI

Yea Bin Cho,

In Young Ko, Hyun Jung Kim

и другие.

International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 140374 - 140374

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Alisol B 23‐Acetate Down‐Regulated GRP94 to Restore Endoplasmic Reticulum Homeostasis on Non‐Alcoholic Steatohepatitis DOI Creative Commons
Fei Qu, Yuming Wang, Yanping Zhang

и другие.

Food Science & Nutrition, Год журнала: 2025, Номер 13(3)

Опубликована: Март 1, 2025

Non-alcoholic steatohepatitis (NASH) poses a serious threat to human health. Alisol B 23-Acetate (AB23A) has shown beneficial effects on NASH, but its mechanism of action remains unclear. We conducted in vitro experiments by inducing L02 cell damage with free fatty acids (FFA) and administering various concentrations AB23A. found that AB23A intervention reduced triglyceride (TG) levels FFA-induced cells improved cellular steatosis. Transcriptomic analysis revealed significantly downregulated glucose-regulated protein 94 (Grp94), indicating primarily regulates the processing pathway endoplasmic reticulum. Within this pathway, also reticulum stress (ERS)-related genes (PERK, eIF2α, ATF4) ER-associated degradation (ERAD)-related (FBXO2, DERL, HSP90AA1). When we silenced GRP94, regulatory TG levels, steatosis, ERS-related proteins (p-PERK/PERK, p-eIF2α/eIF2α, ATF4), ERAD-related HSP90α) disappeared. In vivo, promoted recovery liver index NASH mice, hepatic inflammatory infiltration lipid deposition, serum alanine aminotransferase (ALT) aspartate (AST) activities, levels. RT-qPCR Western blot results demonstrated dose-dependently gene expression GRP94 ERS- factors. There was no significant difference between high-dose PPC intervention. This study demonstrated, through both vivo experiments, improves effect may be related downregulation which suppresses ERS ERAD, thereby restoring ER homeostasis.

Язык: Английский

Процитировано

0
Unveiling the Therapeutic Role of Penfluridol and BMS-754807: NUDT5 Inhibition in Breast Cancer DOI Creative Commons

Majed S. AlFayi,

Mοhd Saeed, Irfan Ahmad

и другие.

Chemical Physics Impact, Год журнала: 2025, Номер unknown, С. 100871 - 100871

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
The structural and functional dynamics of BiP and Grp94: opportunities for therapeutic discovery DOI
Ikponwmosa Obaseki,

Chioma C Ndolo,

Ayodeji Adeola Adedeji

и другие.

Trends in Pharmacological Sciences, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer DOI Creative Commons
Desh Deepak Singh, Shafiul Haque, Youngsun Kim

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 10, 2024

Triple-negative breast cancer (TNBC) stands as the most complex and daunting subtype of affecting women globally. Regrettably, treatment options for TNBC remain limited due to its clinical complexity. However, immunotherapy has emerged a promising avenue, showing success in developing effective therapies advanced cases improving patient outcomes. Improving treatments involves reducing side effects, minimizing systemic toxicity, enhancing efficacy. Unlike traditional immunotherapy, engineered nonmaterial's can precisely target TNBC, facilitating immune cell access, antigen presentation, triggering lasting responses. Nanocarriers with enhanced sensitivity specificity, specific cellular absorption, low toxicity are gaining attention. Nanotechnology-driven immunoengineering strategies focus on targeted delivery systems using multifunctional molecules precise tracking, diagnosis, therapy TNBC. This study delves into TNBC's tumour microenvironment (TME) remodeling, therapeutic resistance, nanotechnology.

Язык: Английский

Процитировано

0